Filing Flows › Organon (OGN) › Guidance & outlook
Organon (OGN) guidance and outlook
Organon's 10-Q filed Oct 30, 2026 makes 10 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Oct 30, 2026
- In January 2026, we divested Jada to Laborie for an aggregate payment of up to $465 million, comprised of consideration of $440 million, subject to certain closing adjustments, plus potential contingent consideration payments of up to $25 million based on the achievement of certain 2026 net sales targets.
- We expect VBP to continue to negatively impact our general medicines product portfolio for the next several quarters.
- Due to changing market conditions, including ongoing regional conflicts in the Middle East and elsewhere, new and evolving U.S. and international tariffs, U.S. tax law changes and regulatory uncertainty that impact our business, as well as the pharmaceutical industry, we have been and will continue to adapt our business and sales strategies to address this changing landscape in order to achieve our business…
- Outside of the U.S., sales for the nine months ended September 30, 2026 were positively impacted by increased demand and access in Brazil, which we expect to continue for the remainder of 2026.
- We anticipate launching Vtama in certain international markets in 2026 and beyond, subject to health authority reviews and approvals.
- We have historically generated and expect to continue to generate positive cash flow from operations.
- Our ability to fund our operations and anticipated capital needs is reliant upon the generation of cash from operations, supplemented as necessary by periodic utilization of our revolving credit facility.
- Our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures, repayment of borrowings, strategic business development transactions and the payment of dividends.
- As part of our post-spinoff plan to further optimize our manufacturing and supply network, we will continue to separate our supply chain through planned exits from supply agreements with Merck through 2031.
- We anticipate continuing to incur costs associated with this separation, including but not limited to accelerated depreciation, exit premiums and fees, technology transfer costs, stability and qualification batch costs, one-time resourcing costs, regulatory and filing costs, capital investment, and inventory stock bridges.
Organon's latest quarter
Organon, Q3 2026: revenue $1.6B (-2% year over year), operating margin 16.2%, net earnings $164M, operating cash flow $370M. The chart follows the revenue to costs, profit and cash.
Questions
What does Organon expect?
In January 2026, we divested Jada to Laborie for an aggregate payment of up to $465 million, comprised of consideration of $440 million, subject to certain closing adjustments, plus potential contingent consideration payments of up to $25 million based on the achievement of certain 2026 net sales targets. We expect VBP to continue to negatively impact our general medicines product portfolio for the next several quarters. Due to changing market conditions, including ongoing regional conflicts in the Middle East and elsewhere, new and evolving U.S. and international tariffs, U.S. tax law changes
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.